Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.32 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6862617 | 1.00 | HCAR2 (0.33) | HCAR2TSHRZDHHC20ZDHHC2CA1 | |
| SCHEMBL27759852 | 0.98 | HCAR2 (0.35) | HCAR2TSHRZDHHC20ZDHHC2CA1 | |
| SCHEMBL27957601 | 0.98 | HCAR2 (0.35) | HCAR2TSHRZDHHC20ZDHHC2CA1 | |
| SCHEMBL27894234 | 0.98 | HCAR2 (0.35) | HCAR2TSHRZDHHC20ZDHHC2CA1 | |
| SCHEMBL4361308 | 0.93 | — | — | |
| SCHEMBL1878200 | 0.93 | — | — | |
| SCHEMBL4359998 | 0.84 | — | — | |
| SCHEMBL4360002 | 0.84 | — | — | |
| SCHEMBL7830676 | 0.79 | — | — | |
| SCHEMBL16994989 | 0.78 | THRB (0.41) | TSHRCA1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040010150-A1 | Process for making 2-amino-5-cyanothiazole compounds | ZHAO MATTHEW M (US) | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010150-A1 | Process for making 2-amino-5-cyanothiazole compounds | ERBB2, ERBB4, EGFR | HCAR2 578/4885TSHR 660/4885ZDHHC20 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.